Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;6(6):100306.
doi: 10.1016/j.esmoop.2021.100306. Epub 2021 Nov 10.

Vaccine third dose and cancer patients: necessity or luxury?

G Pappas  1 , E Saloustros  2 , A Boutis  2 , N Tsoukalas  2 , M Nikolaou  2 , A Christopoulou  2 , S Agelaki  2 , I Boukovinas  2 , A Ardavanis  2 , Z Saridaki  3
Affiliations
Review

Vaccine third dose and cancer patients: necessity or luxury?

G Pappas et al. ESMO Open. 2021 Dec.

Abstract

The current state of the SARS-CoV-2 pandemic is an equilibrium between expanding vaccine coverage on the one hand, and emergence of variants of concern which compromise vaccine effectiveness and enhance viral transmission on the other. Inequity in vaccine distribution, primarily an ethical issue, challenges this equilibrium, as industrialized countries prepare to administer a third booster dose to their population. Solid tumor cancer patients typically respond well to initial full vaccination and someone could argue that they should not be prioritized for an adjuvant third dose, since protection from severe disease has largely been achieved with the two-dose regimen. Nevertheless, their immune status is dynamic and not all of them exhibit an adequate immune response. A booster third dose is necessary for the inadequate responders, while it will result in better protection of all patients from mild disease as well, which if presented could have ominous consequences due to their overall frailty, and their need to adhere to strict therapeutic schemes. International scientific and public health communities should develop approaches that allow for wide immediate vaccination coverage of the developing world, in parallel with administration of adjuvant doses to solid tumor cancer patients (and other at-risk categories) of the developed nations, in order to avoid prolonging the pandemic, which will be prospectively against cancer patients' best interest.

Keywords: cancer patients; delta variant; vaccine inequity; vaccine third dose.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

References

    1. Brown C.M., Vostok J., Johnson H., et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings — Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;(70):1059–1062. - PMC - PubMed
    1. Mlocochova P., Kemp S.A., Dhar M.S., et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. Nature. 2021;599:114–119. - PMC - PubMed
    1. Kang M., Xin H., Yuan J., et al. Transmission dynamics and epidemiological characteristics of Delta variant infections in China. Merdxiv. 2021 doi: 10.1101/2021.08.12.21261991. - DOI - PMC - PubMed
    1. Hall V.G., Ferreira V.H., Ku T., et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–1246. - PMC - PubMed
    1. Twohig K.A., Nuberg T., Zaidi A., et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00475-8. In press. - DOI - PMC - PubMed